Abliva
ABLI | ST
Overview
Corporate Details
- ISIN(s):
- SE0002575340
- LEI:
- 5493005YV22OTMUHZ183
- Country:
- Sweden
- Address:
- Medicon Village, 223 81 Lund
- Website:
- https://abliva.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, will enter the clinic in 2022.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Abliva.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-03 13:10 |
Delisting Announcement
Delisting of the shares of Abliva: last day of trading 17 March 2025
|
English | 64.3 KB | |
| 2025-03-03 13:10 |
Delisting Announcement
Avnotering av aktierna i Abliva: sista handelsdag 17 mars 2025
|
Swedish | 64.1 KB | |
| 2025-02-26 08:30 |
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting in Abliva AB (publ)
|
English | 74.8 KB | |
| 2025-02-26 08:30 |
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Abliva AB (publ)
|
Swedish | 75.2 KB | |
| 2025-02-25 09:50 |
Delisting Announcement
Abliva applies for delisting and will convene an extraordinary general meeting
|
English | 64.9 KB | |
| 2025-02-25 09:50 |
Delisting Announcement
Abliva ansöker om avnotering och kommer att kalla till extra bolagsstämma
|
Swedish | 65.1 KB | |
| 2025-02-21 14:41 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.6 KB | |
| 2025-02-21 08:30 |
Annual Report
|
Swedish | 2.6 MB | |
| 2025-02-21 08:30 |
Annual Report
|
English | 2.6 MB | |
| 2025-02-12 11:37 |
Major Shareholding Notification
|
Swedish | 9.5 KB | |
| 2025-02-11 15:52 |
Major Shareholding Notification
|
Swedish | 9.7 KB | |
| 2024-12-15 20:00 |
M&A Activity
Uttalande från Ablivas styrelse med anledning av Pharmings kontanta offentliga …
|
Swedish | 83.3 KB | |
| 2024-12-15 20:00 |
M&A Activity
Statement by the Board of Directors of Abliva regarding the public cash offer f…
|
English | 80.9 KB | |
| 2024-11-29 18:00 |
Quarterly Report
|
Swedish | 2.9 MB | |
| 2024-11-29 18:00 |
Quarterly Report
|
English | 2.9 MB |
Automate Your Workflow. Get a real-time feed of all Abliva filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Abliva via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-07 | David Bejker | Other | Sell | 269,005 | 121,052.25 SEK |
| 2024-05-31 | Catharina Janzon Johansson | Other | Other | 2,000,000 | 60,000.00 SEK |
| 2024-05-28 | David Laskow-Pooley | Other | Other | 1,000,000 | 30,000.00 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 54,128 | 11,664.58 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 38,000 | 8,151.00 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 36,064 | 7,807.86 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 15,091 | 3,267.20 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,901 | 2,588.47 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,270 | 2,479.40 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,275 | 2,474.86 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Lytix Biopharma AS | Norway | LYTIX | |
|
MaaT Pharma | France | MAAT | |
|
Mabion S.A. | Poland | MAB | |
|
Marinomed Biotech AG | Austria | MARI | |
|
Matricelf Ltd. | Israel | MTLF | |
|
MDxHealth SA | Belgium | MDXH | |
|
Medesis Pharma S.A. | France | ALMDP | |
|
Medica | Italy | MDC | |
|
Medicofarma Biotech Spolka Akcyjna | Poland | MDB | |
|
Medigene AG | Germany | MDG1 |